Risk factors for occult metastasis detected by inflammation-based prognostic scores and tumor markers in biliary tract cancer

Table 4 Tumor markers, inflammation-based prognostic scores and survival time according to type of biliary tract cancers

Variables	Type of cancer
	IBDC	EBDC	GBC	Vater C
	(n = 39)	(n = 110)	(n = 50)	(n = 37)
Tumor markers
CA19-9 (IU/mL)1	7904 ± 3316	1356 ± 506	832 ± 371	22 ± 36
CEA (ng/mL) 1	12.2 ± 26.8	4.0 ± 7.5	8.4 ± 22.0	3.2 ± 3.5
Inflammation-based prognostic scores
NLR1	3.04 ± 1.60	2.83 ± 2.20	3.22 ± 2.27	2.74 ± 2.04
PLR1	151.1 ± 56.9	174.0 ± 95.4	176.6 ± 99.2	163.2 ± 109.9
PNI1	48.0 ± 5.5	45.3 ± 24.5	46.7 ± 7.0	47.1 ± 7.1
mGPS (A / B, C, D)	10/29	47/63	32/18	10/27
Cumulative survival time (%)2
1-year	65.0	80.1	82.6	94.6
3-year	48.3	35.7	63.2	75.3
5-year	31.3	26.4	45.8	75.3

¹Data are presented as the mean ± SD.

²Kaplan-Meier analysis. IBDC: Intrahepatic bile duct cancer; EBDC: Extrahepatic bile duct cancer; GBC: Gallbladder cancer; Vater C: Cancer of the papilla of Vater; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; PNI: Prognostic nutrition index; mGPS: Modified Glasgow prognostic score.